Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 18/20 | 0.74 |
| ▸ | AGTR2 | P50052 | 7/20 | 0.73 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | MME | P08473 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4876944 | 1.00 | AGTR1 (0.74) | AGTR1AGTR2PPARGMME | |
| SCHEMBL4888433 | 1.00 | AGTR1 (0.74) | AGTR1AGTR2PPARGMME | |
| SCHEMBL4887623 | 0.92 | AGTR1 (0.75) | AGTR1AGTR2PPARG | |
| SCHEMBL4887614 | 0.92 | AGTR1 (0.75) | AGTR1AGTR2PPARG | |
| SCHEMBL4887751 | 0.91 | AGTR1 (0.76) | AGTR1AGTR2PPARG | |
| SCHEMBL4887757 | 0.91 | AGTR1 (0.76) | AGTR1AGTR2PPARG | |
| SCHEMBL4884276 | 0.90 | AGTR1 (0.76) | AGTR1AGTR2PPARG | |
| SCHEMBL4884263 | 0.90 | AGTR1 (0.76) | AGTR1AGTR2PPARG | |
| SCHEMBL4887878 | 0.90 | AGTR1 (0.76) | AGTR1AGTR2PPARG | |
| SCHEMBL4888075 | 0.89 | AGTR1 (0.71) | AGTR1AGTR2PPARGMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9198899-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-20140107120-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-8637676-B2 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2162442-B1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107120-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885PPARG 1705/4885 |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | AGTR1, REN, AGTR2 | AGTR1 1/4885AGTR2 3/4885PPARG 1705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.